FTC blocks Abbott, Alza merger
The proposed merger between Abbott Laboratories and Alza Corp. will not be completed due to an inability to come to terms with the FTC.
The $7.3 billion proposed merger between Abbott Park, IL-based Abbott Laboratories and Palo Alto, CA-based Alza Corp. will not be completed due to an inability to come to terms with the Federal Trade Commission, according to Abbott Laboratories.
The deal, which would have been the largest in Abbott history, would have enhanced Abbott's positions in urology and neuroscience. It would have also strengthened Abbott's internal cancer research and development efforts (see Pharmaceutical Representative, August 1999).
"We are obviously disappointed that we were unable to complete this transaction," said Miles D. White, chairman and chief executive officer of Abbott. "Together with Alza, we have worked diligently over the last five months to successfully resolve the issues with the FTC, but could not reach a solution that was in the best interest of our shareholders."
Despite the inability to conclude the merger, White made it clear that the setback would not negatively impact Abbott's future. "It's important to note that our proposed acquisition of Alza was only one aspect of our overall growth strategy," said White. "The fundamentals of our business remain strong, and we've made excellent progress in building our pharmaceutical pipeline this year [by] adding 13 new products. Over the next 12 to 19 months, we plan to launch 14 new pharmaceutical products that will provide acceleration of our growth rate." PR
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Beyond the Prescription: The Role Pharma Plays in Digital Health Conversations
April 1st 2025As social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective digital engagement to build trust and facilitate meaningful healthcare conversations.
